875558-38-6

Basic information

• Product Name: Quinoxaline-6-carboxylic acid methoxy-methyl-amide
• Synonyms: Quinoxaline-6-carboxylic acid methoxy-methyl-amide;N-(Methoxymethyl)quinoxaline-6-carboxamide;N-methoxy-N-methylquinoxaline-6-carboxamide
• CAS NO: 875558-38-6
• Molecular Formula: C11H11N3O2
• Molecular Weight: 217.22394
• Mol File: 875558-38-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Quinoxaline-6-carboxylic acid methoxy-methyl-amide(CAS DataBase Reference)
• NIST Chemistry Reference: Quinoxaline-6-carboxylic acid methoxy-methyl-amide(875558-38-6)
• EPA Substance Registry System: Quinoxaline-6-carboxylic acid methoxy-methyl-amide(875558-38-6)

Safety Data

• Hazardous Substances Data: 875558-38-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
Quinoxaline-6-carboxylic acid methoxy-methyl-amide is used as a key intermediate in the synthesis of bioactive molecules and pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Materials Science:
Quinoxaline-6-carboxylic acid methoxy-methyl-amide may also have uses in materials science due to its chemical properties and structure, potentially contributing to the development of new materials with specific characteristics.
Used in Agrochemicals:
Additionally, Quinoxaline-6-carboxylic acid methoxy-methyl-amide may find applications in the agrochemical industry, where it could be utilized in the development of new pesticides or other agricultural chemicals to improve crop protection and yield.

Upstream product

• 6925-00-4 quinoxaline-6-carboxylic acid 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 543-27-1 isobutyl chloroformate 
• 258503-93-4 quinoxaline-6-carbonyl chloride 
• 1117-97-1 N,0-dimethylhydroxylamine 

Downstream Products

• 1428663-52-8 N-(2,4-difluoro-3-(hydroxy(quinoxalin-6-yl)methyl)phenyl)pivalamide 
• 1428663-53-9 N-(2,4-difluoro-3-(hydroxy(quinoxalin-6-yl)methyl)phenyl)pivalamide 
• 1427632-42-5 1-(2,4-difluoro-3-(quinoxaline-6-carbonyl)phenyl)-3-(3-fluorophenyl)urea 
• 1427633-10-0 N-(2,4-difluoro-3-(quinoxaline-6-carbonyl)phenyl)-3-fluorobenzamide 
• 1428663-49-3 tert-butyl (2,4-difluoro-3-(quinoxaline-6-carbonyl)phenyl)carbamate 
• 1425485-86-4 C₁₉H₁₇F₂N₃O₃S₂ 
• 1425485-82-0 C₁₈H₁₄F₃N₃O₃S 
• 1425486-29-8 N-(propylsulfonyl)-N-(2,4,5-trifluoro-3-(quinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide 
• 1425487-57-5 (3-amino-2,5,6-trifluorophenyl)(quinoxalin-6-yl)methanone 
• 1427631-49-9 1-(4-fluoro-3-(quinoxaline-6-carbonyl)phenyl)-3-(3-fluorophenyl)urea 
• 1425486-44-7 (5-amino-2-fluorophenyl)(quinoxalin-6-yl)methanone 
• 1425486-43-6 N-(4-fluoro-3-(quinoxaline-6-carbonyl)phenyl)pivalamide 
• 1425486-42-5 N-(4-fluoro-3-(hydroxy(quinoxalin-6-yl)methyl)phenyl)pivalamide 
• 1427632-71-0 3-fluoro-N-(4-fluoro-3-(quinoxaline-6-carbonyl)phenyl)benzamide 

Relevant articles and documents

ANTI-HCMV COMPOSITIONS AND METHODS

Novel compounds useful for treating and/or preventing HCMV infections are provided.

CERTAIN CHEMICAL ENTITES, COMPOSITIONS, AND METHODS

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described. Specifically quinoxaline derivatives of Formula I and their use in modulating the activity of Braf and/or mutant Braf kinase to reg

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions c

Certain Chemical Entities, Compositions, and Methods

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of using these chemical entities, e.g., for treatment of cancer are described.

Pyrazolone based TGFβR1 kinase inhibitors

Interruption of TGFβ signaling through inhibition of the TGFβR1 kinase domain may prove to have beneficial effect in both fibrotic and oncological diseases. Herein we describe the SAR of a novel series of TGFβR1 kinase inhibitors containing a pyrazolone core. Most TGFβR1 kinase inhibitors described to date contain a core five-membered ring bearing N as H-bond acceptor. Described herein is a novel strategy to replace the core structure with pyrazolone ring, in which the carbonyl group is designed as an H-bond acceptor to interact with catalytic Lys 232.

Substituted Pyrazalones

The invention is related to compounds of formula (I) as antagonists of the TGFβ family type I receptors, Alk5 and/or AIk 4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such a

PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES

The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.

SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE

The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment. The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes